---
schema_version: "secwatch.filing_event.v1"
accession: "0001680367-22-000007"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2022-03-15T23:59:59+00:00"
generated_at: "2026-06-26T22:50:19.135556+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs reports Q4 net income $7.8M, cash $268.8M; presents initial clinical data for SL-172154 and SL-279252

## Summary
- Q4 2021 net income $7.8M ($0.18 diluted) vs net loss $12.0M in Q4 2020; full year net loss $45.0M vs $36.6M.
- Revenue $30.1M in Q4 (up from $1.3M) due to Takeda collaboration revenue recognition; R&D expenses $16.2M.
- Cash $268.8M as of Dec 31, 2021, sufficient into second half 2024.
- Initial clinical data for SL-172154 in ovarian cancer showed favorable safety, target occupancy, and CD40 activation; combination trial planned.
- SL-279252 showed anti-tumor activity including partial response in ocular melanoma; dose escalation continues to 24 mg/kg.

## SEC filing metadata
- accession: 0001680367-22-000007
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2022-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000168036722000007/0001680367-22-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000168036722000007/sttk-20220315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001680367-22-000007
- JSON: https://secwatch.observer/filing/0001680367-22-000007.json
- Plain text: https://secwatch.observer/filing/0001680367-22-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.